Table 2.

Anticancer drug concomitantly used from ICI administration to the time of thyroid-related irAE.

Anticancer drug	Grade 2-4
ICI only (%)	61.1
Bevacizumab (%)	11.1
Axitinb (%)	9.3
Carboplatin, pemetrexed (%)	7.4
Cabozantinib (%)	5.6
Lenvatinib (%)	3.7
5-Fluorouracil (%)	1.9
Anticancer drug	Grade 1
ICI only (%)	70.2
Bevacizumab (%)	8.8
Carboplatin, etoposide (%)	7.0
Carboplatin, pemetrexed (%)	5.3
Carboplatin, paclitaxel (%)	5.3
Axitinb (%)	1.8
Ramucirumab (%)	1.8

ICI, immune checkpoint inhibitor.